METHODS
Data of 105 mRCC patients treated and monitored at our center
between 2006–2013 was studied retrospectively.
RESULTS
Median age was 57 years. Of the patients, 67% was male. The
rate of non-clear cell subtype was 13%. Seventy-one percent
of the patients received sunitinib without interruption where
objective response rate was 20%. The most common grade 3–4
toxicity was anemia (15%). Median progression-free survival
(PFS) and overall survival (OS) were 9 and 21 months, respectively.
In multivariate analysis, sunitinib treatment unresponsiveness
(p<0.001) had a negative impact on PFS whereas
treatment unresponsiveness (p<0.001) and absence of surgery
(p=0.05) were the factors that decreased OS.
CONCLUSION
Median duration of PFS and OS was consistent with the literature
despite the fact that relatively poor prognostic group
of patients were included and more dose modifications were
needed due to toxicicity in our study.
Keywords: Response rate; poor prognosis groups; metastatic renal cell carcinoma; survival; sunitinib
